tanespimycin
Trials 34
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tanespimycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00514371 ↗ |
| Known as | 17-(Allylamino)-17- Demethoxygeldanamycin | “A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis” NCT00132015 ↗ |
| Known as | 17-AAG | “A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis” NCT00132015 ↗3“17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with refractory or advanced solid tumors or hematologic malignancies.” NCT00004065 ↗ “A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies” NCT00820768 ↗ “CNF1010 (17-AAG)” NCT00319930 ↗ |
| Known as | 17-N-allylamino-17-demethoxy Geldanamycin | “Determine the 1-year treatment failure rate in patients with inoperable locoregionally advanced or metastatic medullary or differentiated thyroid carcinoma treated with...” NCT00118248 ↗3“Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients” NCT00087386 ↗ “17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol” NCT00004065 ↗ “Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours” NCT00132015 ↗ |
| Known as | CNF1010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00319930 ↗ |
| Known as | KOS-953 | “This is a phase 3, open label trial for patients with multiple myeloma in first relapse. Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of...” NCT00546780 ↗1“Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.” NCT00514371 ↗ |
| Known as | NSC #330507 | “A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis” NCT00132015 ↗2“Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients” NCT00087386 ↗ “17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol” NCT00004065 ↗ |
| Action | Inhibit | “target inhibition (c-RAF-1 inhibition in four of six patients” PMID 15961763 ↗ Jun 2005 |
| Route | Intravenous | “IV over 15-30 minutes” NCT00003969 ↗ |